Actively Recruiting
Effect of Transpulmonary Mechanical Power on the Prognosis of Patients With Severe Acute Respiratory Distress Syndrome Treated With Venovenous Extracorporeal Membrane Oxygenation
Led by Beijing Chao Yang Hospital · Updated on 2025-07-03
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients with severe acute respiratory distress syndrome (ARDS) who are receiving venovenous extracorporeal membrane oxygenation (VV-ECMO) support. The study aims to explore how transpulmonary mechanical power, which measures the energy delivered directly to lung tissue during mechanical ventilation, may predict the prognosis of these patients. Despite advances in VV-ECMO treatment, mortality remains high, and understanding mechanical power's role could improve patient outcomes. The study observes the use of transpulmonary pressure to guide ventilator settings in patients with severe ARDS treated with VV-ECMO. This observational approach monitors patients receiving standard VV-ECMO support, focusing on how transpulmonary mechanical power influences their treatment process. No experimental drugs or additional interventions are mentioned. Participants will be monitored for their ability to be successfully weaned from VV-ECMO within 60 days after enrollment. Researchers will also track 60-day mortality rates. The study involves collecting clinical data related to ventilation settings, patient response, and outcomes during and after VV-ECMO treatment. The total observation period for outcome assessment is 60 days post-enrollment.
CONDITIONS
Brief Title
Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the diagnostic criteria of Berlin's definition for ARDS
- Receiving VV-ECMO support
- Aged between 18 and 75 years
You will not qualify if you...
- Patients on mechanical ventilation with peak pressure over 35 cm H2O and FiO2 greater than 0.8 for more than 7 days
- Contraindication to heparinization
- Irreversible neurological injury
- Severe chronic lung disease with life expectancy less than 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 60 days after enrollment
Participants receiving VV-ECMO support are observed with transpulmonary pressure measurements used to guide ventilator settings.
Visits occur as part of routine clinical care during VV-ECMO support
Trial Site Locations
Total: 1 location
1
Beijing Chao-Yang Hospital
Beijing, Beijing Municipality, China, 100020
Actively Recruiting
Research Team
Y
Yu Zhao, Dr.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here